The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Are The Forecasted Market Size Figures For The Esketamine Market In 2026 And 2030?
The esketamine market has experienced significant expansion in recent years. It is anticipated to increase from $1.51 billion in 2025 to $1.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.8%. The growth observed in the past can be attributed to several factors, including unmet needs in major depressive disorder, the inherent limitations of traditional antidepressants, regulatory approvals granted for nasal esketamine, a heightened awareness of mental health, and the expansion of specialty psychiatric clinics.
The esketamine market size is projected for substantial expansion in the coming years. It will grow to $2.5 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. This anticipated growth during the forecast period stems from factors such as the rising incidence of treatment-resistant depression, the need for quick-acting treatments, the broader availability of supervised outpatient administration, the development of mental health infrastructure, and ongoing investment in clinical research. Key developments expected during this period involve the increasing use for treatment-resistant depression, the wider application of nasal spray administration, a rise in its deployment within acute psychiatric care settings, enhanced oversight and regulated supply, and continuous exploration into rapidly effective antidepressants.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp
What Important Drivers Are Powering The Esketamine Market Growth?
The anticipated expansion of the esketamine market in upcoming years is linked to the growing occurrence of treatment-resistant depression (TRD). TRD is defined as depression that fails to improve even after individuals have undergone at least two distinct antidepressant treatments, administered correctly and for an adequate period. The rise in TRD cases stems from the inadequate effectiveness of traditional antidepressants, which often results in enduring and recurring bouts of depression. Esketamine addresses TRD through a rapid-onset mechanism that targets NMDA receptors, providing a viable treatment option for those unaffected by standard antidepressant therapies. For example, the National Institute of Mental Health (NIMH), a federal agency located in the U.S., stated in September 2023 that approximately 30% of major depressive disorder patients in the U.S. showed resistance to conventional treatments in 2023. Consequently, the escalating frequency of treatment-resistant depression is a key factor propelling the expansion of the esketamine market.
Which Segment Groups Define The Esketamine Market Landscape?
The esketamine market covered in this report is segmented –
1) By Formulation Type: Nasal Spray, Injectable Form
2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior
3) By Patient Type: Adult Patients
4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics
5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
Subsegments:
1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy
2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine
What Trends Are Affecting The Growth Of The Esketamine Market?
Major companies operating in the esketamine market are concentrating on developing advanced treatment solutions, such as monotherapy, to enhance depressive symptom relief beyond what a placebo offers. Monotherapy refers to the use of a single drug or treatment to manage a disease or medical condition, rather than combining multiple therapies. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trials, the approval demonstrated that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements observed within 24 hours. This breakthrough provides a critical option for approximately 30% of individuals who do not respond to traditional antidepressants, eliminating the need for concurrent oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to address potential side effects. This milestone marks a significant advancement in TRD treatment, offering renewed hope for improved patient outcomes.
Which Firms Are Competing In The Esketamine Market?
Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.
Access The Complete Esketamine Market Report:
https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report
Which Geographic Region Represents The Largest Esketamine Market Share?
North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Esketamine Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp
Browse Through More Reports Similar to the Global Esketamine Market 2026, By The Business Research Company
Epinephrine Market Report 2026
https://www.thebusinessresearchcompany.com/report/epinephrine-global-market-report
Anti Infective Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market
Anticholinergic Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model